Monovisc is a brand of intraarticular injections made of sodium hyaluronate. It is developed by Anika Therapeutics, a multinational medicine technology company specialized in the development of hyaluronic acid (HA) therapeutic products. Based in Massachusetts, the company provides innovative pain management solutions for orthopedic patients around the world. The naturally sourced HA in Monovisc injections are extensively purified using a proprietary technology. Monovisc has been approved by the Food and Drug Administration (FDA) since February 2014.
Monovisc injections can provide pain relief that lasts up to 6 months.
Monovisc injections have an excellent safety profile and can be used confidently. They have been approved for use in the US and Canada. Patients should not use Monovisc injections if they are hypersensitive to any of their active and inactive components. Apart from that, they should not be used on individuals with known systemic bleeding disorder, infection of the index joint or pre- existing infections of the skin around the injection site. For more safety information on Monovisc products (including information on the contraindications of these products), refer to the package insert enclosed.
Some of the side effects of these products include but are not limited to the following:
Monovisc products involve little-to-no recovery time, as they are administered via a minimally invasive procedure.
Monovisc products range in price from $329.00 to $349.00.